Drug intelligence / Profile preview

5101

Development stage: Unknown
Lead developer: Lakefront Biotherapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

5101 is a CD19-targeted chimeric antigen receptor T-cell (CAR-T) therapy under development by Lakefront Biotherapeutics. The drug consists of autologous T cells genetically engineered to express a chimeric antigen receptor (CAR) specific for the CD19 protein, a biomarker found on the surface of B cells. By targeting CD19, 5101 aims to eliminate malignant B cells in Non-Hodgkin Lymphoma (NHL) and potentially pathogenic B cells in autoimmune conditions like Systemic Lupus Erythematosus (SLE). It is currently being evaluated in Phase 1 clinical trials for NHL and is in the preclinical stage for SLE.

Targets

TNFRSF9 (CD137 extracellular domain)CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on 5101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 5101.